The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.

Sanofi and Regeneron have announced positive results from trials of novel drug alirocumab, which targets PCSK9, in people ... last week for its rival PCSK9 inhibitor drug evolocumab.

Leqvio should be avoided during pregnancy due to the potential to cause fetal harm based on its mechanism ... PCSK9 to reduce LDL-C. It is one of two medications in the PCSK9 inhibitor drug ...